Dr. Uday Kompella is a Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering at University of Colorado, Anschutz Medical Campus, with research interests in the areas of drug discovery, drug delivery, and nanotechnology for treating a variety of degenerative, neovascular, and inflammatory disorders including retinitis pigmentosa, age-related macular degeneration (AMD), diabetic retinopathy, and cancers. Ocugen, Inc. is a public company co-founded by Dr. Kompella. Dr. Kompella is a Fellow of the American Association of Pharmaceutical Scientists (AAPS), the Association for Research in Vision and Ophthalmology (ARVO). and the Association for Ocular Pharmacology and Therapeutics (AOPT) and serves as the Editor-in-Chief for the journals Expert Opinion on Drug Delivery and Journal of Ocular Pharmacology and Therapeutics. He served as an editor for the journal, Pharmaceutical Research, for sixteen years. Dr. Kompella is a recipient of the Distinguished Scientist Award (University of Nebraska Medical Center), Distinguished Teacher Award (University of Nebraska Medical Center), Dean’s Mentoring Award and Innovations in Science Award (University of Colorado Anschutz Medical Campus), and Undergraduate Alumni Teaching Excellence Award (Auburn University). He is also a recipient of the ARVO Foundation for Eye Research/Pfizer Ophthalmics/Carl Camras Translational Research Award in Ophthalmology. Dr. Kompella obtained his PhD in Pharmaceutical Sciences from the University of Southern California.